These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

102 related items for PubMed ID: 8782861

  • 1. In vitro neuroprotective properties of the novel cholinergic channel activator (ChCA), ABT-418.
    Donnelly-Roberts DL, Xue IC, Arneric SP, Sullivan JP.
    Brain Res; 1996 May 06; 719(1-2):36-44. PubMed ID: 8782861
    [Abstract] [Full Text] [Related]

  • 2. In vitro pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107.
    Malysz J, Anderson DJ, Grønlien JH, Ji J, Bunnelle WH, Håkerud M, Thorin-Hagene K, Ween H, Helfrich R, Hu M, Gubbins E, Gopalakrishnan S, Puttfarcken PS, Briggs CA, Li J, Meyer MD, Dyhring T, Ahring PK, Nielsen EØ, Peters D, Timmermann DB, Gopalakrishnan M.
    J Pharmacol Exp Ther; 2010 Sep 01; 334(3):863-74. PubMed ID: 20504915
    [Abstract] [Full Text] [Related]

  • 3. (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: I. In vitro characterization.
    Arneric SP, Sullivan JP, Briggs CA, Donnelly-Roberts D, Anderson DJ, Raszkiewicz JL, Hughes ML, Cadman ED, Adams P, Garvey DS.
    J Pharmacol Exp Ther; 1994 Jul 01; 270(1):310-8. PubMed ID: 7518514
    [Abstract] [Full Text] [Related]

  • 4. Activation and inhibition of rat neuronal nicotinic receptors by ABT-418.
    Papke RL, Thinschmidt JS, Moulton BA, Meyer EM, Poirier A.
    Br J Pharmacol; 1997 Feb 01; 120(3):429-38. PubMed ID: 9031746
    [Abstract] [Full Text] [Related]

  • 5. Potential treatment of Alzheimer disease using cholinergic channel activators (ChCAs) with cognitive enhancement, anxiolytic-like, and cytoprotective properties.
    Arneric SP, Sullivan JP, Decker MW, Brioni JD, Bannon AW, Briggs CA, Donnelly-Roberts D, Radek RJ, Marsh KC, Kyncl J.
    Alzheimer Dis Assoc Disord; 1995 Feb 01; 9 Suppl 2():50-61. PubMed ID: 8534424
    [Abstract] [Full Text] [Related]

  • 6. ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A potent and selective cholinergic channel modulator with neuroprotective properties.
    Sullivan JP, Donnelly-Roberts D, Briggs CA, Anderson DJ, Gopalakrishnan M, Xue IC, Piattoni-Kaplan M, Molinari E, Campbell JE, McKenna DG, Gunn DE, Lin NH, Ryther KB, He Y, Holladay MW, Wonnacott S, Williams M, Arneric SP.
    J Pharmacol Exp Ther; 1997 Oct 01; 283(1):235-46. PubMed ID: 9336329
    [Abstract] [Full Text] [Related]

  • 7. Nicotine protects cultured cortical neurons against glutamate-induced cytotoxicity via alpha7-neuronal receptors and neuronal CNS receptors.
    Kaneko S, Maeda T, Kume T, Kochiyama H, Akaike A, Shimohama S, Kimura J.
    Brain Res; 1997 Aug 08; 765(1):135-40. PubMed ID: 9310404
    [Abstract] [Full Text] [Related]

  • 8. Relationship between the increased cell surface alpha7 nicotinic receptor expression and neuroprotection induced by several nicotinic receptor agonists.
    Jonnala RR, Buccafusco JJ.
    J Neurosci Res; 2001 Nov 15; 66(4):565-72. PubMed ID: 11746376
    [Abstract] [Full Text] [Related]

  • 9. 5-Iodo-A-85380, a specific ligand for alpha 4 beta 2 nicotinic acetylcholine receptors, prevents glutamate neurotoxicity in rat cortical cultured neurons.
    Ueda M, Iida Y, Kitamura Y, Kawashima H, Ogawa M, Magata Y, Saji H.
    Brain Res; 2008 Mar 14; 1199():46-52. PubMed ID: 18269932
    [Abstract] [Full Text] [Related]

  • 10. (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. In vivo characterization.
    Decker MW, Brioni JD, Sullivan JP, Buckley MJ, Radek RJ, Raszkiewicz JL, Kang CH, Kim DJ, Giardina WJ, Wasicak JT.
    J Pharmacol Exp Ther; 1994 Jul 14; 270(1):319-28. PubMed ID: 7913497
    [Abstract] [Full Text] [Related]

  • 11. ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective analgesic acting via neuronal nicotinic acetylcholine receptors: I. In vitro characterization.
    Donnelly-Roberts DL, Puttfarcken PS, Kuntzweiler TA, Briggs CA, Anderson DJ, Campbell JE, Piattoni-Kaplan M, McKenna DG, Wasicak JT, Holladay MW, Williams M, Arneric SP.
    J Pharmacol Exp Ther; 1998 May 14; 285(2):777-86. PubMed ID: 9580626
    [Abstract] [Full Text] [Related]

  • 12. Nicotine-induced protection against glutamate cytotoxicity. Nicotinic cholinergic receptor-mediated inhibition of nitric oxide formation.
    Shimohama S, Akaike A, Kimura J.
    Ann N Y Acad Sci; 1996 Jan 17; 777():356-61. PubMed ID: 8624112
    [Abstract] [Full Text] [Related]

  • 13. Nicotinic acetylcholine receptor-mediated neuroprotection by donepezil against glutamate neurotoxicity in rat cortical neurons.
    Takada Y, Yonezawa A, Kume T, Katsuki H, Kaneko S, Sugimoto H, Akaike A.
    J Pharmacol Exp Ther; 2003 Aug 17; 306(2):772-7. PubMed ID: 12734391
    [Abstract] [Full Text] [Related]

  • 14. Presynaptic alpha7 and non-alpha7 nicotinic acetylcholine receptors modulate [3H]d-aspartate release from rat frontal cortex in vitro.
    Rousseau SJ, Jones IW, Pullar IA, Wonnacott S.
    Neuropharmacology; 2005 Jul 17; 49(1):59-72. PubMed ID: 15992581
    [Abstract] [Full Text] [Related]

  • 15. Central nicotinic receptor agonists ABT-418, ABT-089, and (-)-nicotine reduce distractibility in adult monkeys.
    Prendergast MA, Jackson WJ, Terry AV, Decker MW, Arneric SP, Buccafusco JJ.
    Psychopharmacology (Berl); 1998 Mar 17; 136(1):50-8. PubMed ID: 9537682
    [Abstract] [Full Text] [Related]

  • 16. New insight into the functional role of acetylcholine in developing embryonic rat retinal neurons.
    Yasuyoshi H, Kashii S, Kikuchi M, Zhang S, Honda Y, Akaike A.
    Invest Ophthalmol Vis Sci; 2002 Feb 17; 43(2):446-51. PubMed ID: 11818389
    [Abstract] [Full Text] [Related]

  • 17. ABT-089: pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disorders.
    Rueter LE, Anderson DJ, Briggs CA, Donnelly-Roberts DL, Gintant GA, Gopalakrishnan M, Lin NH, Osinski MA, Reinhart GA, Buckley MJ, Martin RL, McDermott JS, Preusser LC, Seifert TR, Su Z, Cox BF, Decker MW, Sullivan JP.
    CNS Drug Rev; 2004 Feb 17; 10(2):167-82. PubMed ID: 15179445
    [Abstract] [Full Text] [Related]

  • 18. Primary cultures of rat cortical microglia treated with nicotine increases in the expression of excitatory amino acid transporter 1 (GLAST) via the activation of the α7 nicotinic acetylcholine receptor.
    Morioka N, Tokuhara M, Nakamura Y, Idenoshita Y, Harano S, Zhang FF, Hisaoka-Nakashima K, Nakata Y.
    Neuroscience; 2014 Jan 31; 258():374-84. PubMed ID: 24300109
    [Abstract] [Full Text] [Related]

  • 19. In vivo pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's disease.
    Bitner RS, Bunnelle WH, Decker MW, Drescher KU, Kohlhaas KL, Markosyan S, Marsh KC, Nikkel AL, Browman K, Radek R, Anderson DJ, Buccafusco J, Gopalakrishnan M.
    J Pharmacol Exp Ther; 2010 Sep 01; 334(3):875-86. PubMed ID: 20504913
    [Abstract] [Full Text] [Related]

  • 20. Improvement in performance of a delayed matching-to-sample task by monkeys following ABT-418: a novel cholinergic channel activator for memory enhancement.
    Buccafusco JJ, Jackson WJ, Terry AV, Marsh KC, Decker MW, Arneric SP.
    Psychopharmacology (Berl); 1995 Aug 01; 120(3):256-66. PubMed ID: 8524972
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.